Scarica l'app Stockscreener
1.94
7.78%
0.14
Dopo l'orario di chiusura:
1.96
0.02
+1.03%
Precedente Chiudi:
$1.80
Aprire:
$1.79
Volume 24 ore:
213.46K
Relative Volume:
0.65
Capitalizzazione di mercato:
$4.24M
Reddito:
-
Utile/perdita netta:
$-10.91M
Rapporto P/E:
-0.0244
EPS:
-79.5513
Flusso di cassa netto:
$-12.14M
1 W Prestazione:
-15.28%
1M Prestazione:
+14.12%
6M Prestazione:
-29.45%
1 anno Prestazione:
-95.56%
Intervallo 1D:
$1.78
$2.00
Intervallo di 1 settimana:
$1.76
$3.36
Portata 52W:
$1.36
$80.36
Gri Bio Inc Stock (GRI) Company Profile
Nome
Gri Bio Inc
Settore
Industria
Telefono
(619) 400-1171
Indirizzo
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.94 | 3.94M | 0 | -10.91M | -12.14M | -79.55 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-09 | Iniziato | H.C. Wainwright | Buy |
Gri Bio Inc Borsa (GRI) Ultime notizie
GRI Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10.00 - GuruFocus
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
GRI Bio Reports Positive Phase 2a IPF Biomarker Data - TipRanks
Gri Bio reports Phase 2a data for IPF drug candidate GRI-0621 - Investing.com
GRI Bio posts Phase 2a IPF biomarker and safety data; +99 mL placebo‑adj FVC, supports longer study - TradingView
GRI Bio Reports Phase 2a Data Showing Repair Phenotype and FVC Improvement with GRI-0621 in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
Experimental IPF pill from GRI Bio (GRI) boosts lung function in 12 weeks as company eyes 52-week study - stocktitan.net
Cough during treatment was 0% with GRI Bio's drug, versus 25% on placebo - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
What Put GRI Bio (NASDAQ:GRI) on the Nasdaq Composite Radar? - Kalkine Media
GRI Bio Surges As Phase 2a IPF Drug Data Nears - StocksToTrade
GRI Bio Jumps As Positive IPF Drug Data Nears ERS Stage - timothysykes.com
GRI-0621 Improves FVC, Reduces Fibrotic Biomarkers in IPF - HCPLive
GRI Bio Surges As Phase 2a IPF Data Near ERS Reveal - timothysykes.com
GRI Bio Company Profile & Introduction - Moomoo
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
GRI|GRI Bio Inc|Price:2.880|Chg%:+0.590 - TradingKey
GRI Bio will present data on its once-daily oral drug in Barcelona this September - stocktitan.net
GRI Bio Featured in "Why Now" On-Demand Video Webcast - Yahoo Finance
OSRH Stock Price and Chart — OTC:OSRH - tradingview.com
Fortis (FTS) Financial Results: The Available Earnings Metric Delivers a Beat at the Close; Price Move: Shares Move 0.77% Higher in the Latest ReadingConsensus Beat Rate - vinanet.vn
CHGA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GRI Bio Price Target Cut to $27.00/Share From $32.00 by Ascendiant Capital - Moomoo
GRI Bio will present four sets of data on a potential lung-scarring treatment at ERS 2026 - Stock Titan
GRI (GRI) EPS and Revenue: Reported EPS Misses Expectations in the Latest Reading; Market Move: The Stock Loses 3.47% in the Current UpdateEarnings Forecast Report - vinanet.vn
GRI Bio Inc. (GRI) Climbs 3.6% to $1.73 as Buyers Defend Key SupportWyckoff Accumulation - vinanet.vn
GRI Bio Inc. Q1 2026 Earnings: Wider-than-Expected Loss of $1.61 Per Share, Yet Stock Closes Up 3.59 - vinanet.vn
GRI Q1 2026 Earnings: EPS Falls Sharply Short of Estimates as Shares Slide 5.65%Earnings Forecast Report - vinanet.vn
GRI Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
GRI Bio, Inc. 2Q 2026: Net income $(1.64)M, EPS $(0.91) — 10-Q Summary - TradingView
Form 10-Q GRI Bio, Inc. For: Jun 30 - StreetInsider
GRI Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
GRI Bio (GRI) investors disclose 4.99% stake capped by warrant blockers - Stock Titan
GRI Q2'26 Earnings: revenue estimate is 0 USD - TradingView
GRI Bio Inc expected to post a loss of $1.19 a shareEarnings Preview - TradingView
GRI Bio (GRI) Jumps 15.65% to $1.70 — Breakout Above $1.78 Could Extend RallyFast Moving Stocks - vinanet.vn
GRI Bio Inc (GRI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GRI Bio Inc. (NASDAQ: GRI) Share Price, GRI Stock News, GRI Share Price & Updates - kalkine.ca
GRI Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage BurnBuyback Announcement Report - vinanet.vn
GRI Bio Inc (GRI) Cash Flow - TradingKey
GRI Bio Inc (GRI) Valuation: PE, PB & Fair Value Analysis - TradingKey
GRI Bio Inc (GRI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GRI Bio Inc (GRI) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
GRI|GRI Bio Inc|Price:1.420|Chg%:-0.030 - TradingKey
GRI Bio Inc (GRI) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
GRI Bio Inc (GRI) Income Statement - TradingKey
Gri Bio, Inc. (GRI) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
TradingKey - TradingKey
GRI Bio Inc (GRI) Institutional Confidence - TradingKey
GRI Bio, Inc. Revenue Breakdown – NASDAQ:GRI - TradingView
GRI Bio Inc (GRI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gri Bio Inc Azioni (GRI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):